Helicobacter Pylori Infection and Nonsteroidal Anti-inflammatory Drug Use: Eradication, Acid-Reducing Therapy, or Both?

En-Ling Leung Ki,Francis K. L. Chan
DOI: https://doi.org/10.1016/j.cgh.2012.04.010
IF: 13.576
2012-01-01
Clinical Gastroenterology and Hepatology
Abstract:ScenarioA general health practitioner calls you regarding 3 of his patients on nonsteroidal anti-inflammatory drugs (NSAIDs).He asks you if they could benefit from Helicobacter pylori testing and treating.He also asks you if he should prescribe prophylactic acid-reducing therapy.Patient 1 is a 68-yearold woman recently diagnosed with rheumatoid arthritis in whom your colleague wishes to commence regular NSAIDs.She has a history of uncomplicated peptic ulcer more than a decade ago.Patient 2 is a 71-year-old man on long-term, low-dose aspirin (acetylsalicylic acid [ASA]) for ischemic heart disease.He has a history of peptic ulcer bleed 3 years ago.He reports self-medicating regularly with over-the-counter NSAIDs for osteoarthritis-related pain.Patient 3 is a 40-year-old man with ankylosing spondylitis who is a longterm NSAID user in whom your colleague wishes to uptitrate the dose for better analgesic control.He has no history of peptic ulcer disease and consumes no other medications.
What problem does this paper attempt to address?